Skip to main content

Analysis of continuous firstline treatment with docetaxel and carboplatin for advanced nonsmall cell lung cancer

Buy Article:

$37.00 plus tax (Refund Policy)

The present study aimed to analyze the efficacy and safety of multiple cycles of docetaxel and carboplatin (CBDCA) as a firstline treatment in patients with advanced nonsmall cell lung cancer (NSCLC). Patients with stage III or IV NSCLC, whose treatment began between July 1999 and February 2003, were retrospectively evaluated. Relatively low doses of docetaxel and CBDCA were administered for as many cycles as possible. The primary outcome assessed was the overall survival (OS) time, and the secondary outcomes included progressionfree survival (PFS) time, response rate (RR) and adverse events. The median cycle number was four (range, 212). The median OS time was 400 days, and for adenocarcinoma and nonadenocarcinoma, the OS time was 490 and 192 days, respectively. The median PFS time was 176 days and the RR was 66.7%. The main toxicity of the treatment was neutropenia, with grade 3 or 4 neutropenia occurring in 81.0% of patients. Continuous firstline treatment with this regimen may have encouraging effects within a certain group of advanced NSCLC patients, thereby warranting further investigations.
No Reference information available - sign in for access.
No Citation information available - sign in for access.
No Supplementary Data.
No Article Media
No Metrics

Document Type: Research Article

Affiliations: 1: Division of Respiratory Medicine, Department of Internal Medicine, Tokai University School of Medicine, Isehara, Kanagawa 2591193, Japan 2: Division of Respiratory Medicine, Department of Internal Medicine, Saiseikai Central Hospital, Minatoku, Tokyo 1080073, Japan 3: Department of Thoracic Surgery, Saiseikai Central Hospital, Minatoku, Tokyo 1080073, Japan

Publication date: 2014-06-01

More about this publication?
  • Oncology Letters is a monthly, peer-reviewed journal, available in print and online, that focuses on all aspects of clinical oncology, as well as in vitro and in vivo experimental model systems relevant to the mechanisms of disease.

    The principal aim of Oncology Letters is to provide the prompt publication of original studies of high quality that pertain to clinical oncology, chemotherapy, oncogenes, carcinogenesis, metastasis, epidemiology and viral oncology in the form of original research, reviews and case reports.
  • Editorial Board
  • Information for Authors
  • Submit a Paper
  • Subscribe to this Title
  • Information for Advertisers
  • Terms & Conditions
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more